No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SLRN Acelyrin
- 4.120
- +0.070+1.73%
Close May 31 16:00 ET
- 4.000
- -0.120-2.91%
Post 18:12 ET
407.99MMarket Cap-1696P/E (TTM)
4.300High4.050Low1.38MVolume4.070Open4.050Pre Close5.68MTurnover2.35%Turnover RatioLossP/E (Static)99.03MShares29.88052wk High0.63P/B242.09MFloat Cap3.91052wk Low--Dividend TTM58.76MShs Float29.880Historical High--Div YieldTTM6.17%Amplitude3.910Historical Low4.119Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Piper Sandler Maintains Acelyrin(SLRN.US) With Buy Rating, Maintains Target Price $68
Piper Sandler analyst Yasmeen Rahimi maintains $Acelyrin(SLRN.US)$ with a buy rating, and maintains the target price at $68.According to TipRanks data, the analyst has a success rate of 34.3% and a to
Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Arrowhead Pharmaceuticals (ARWR) and NovoCure (NVCR)
H.C. Wainwright Maintains Acelyrin(SLRN.US) With Buy Rating, Raises Target Price to $18
H.C. Wainwright analyst Emily Bodnar maintains $Acelyrin(SLRN.US)$ with a buy rating, and adjusts the target price from $16 to $18.According to TipRanks data, the analyst has a success rate of 37.3% a
Analysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX), Greenwich LifeSciences (GLSI) and ACELYRIN, INC. (SLRN)
Express News | HC Wainwright & Co. Maintains Buy on Acelyrin, Raises Price Target to $18
Express News | HC Wainwright & Co. Reiterates Buy on Acelyrin, Maintains $16 Price Target
Comments
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
$Acelyrin(SLRN.US$ insider buying?good news soon?
The company's CEO sees Tetrault's extensive experience, especially in global human capital strategy and business operations, as a valuable addition to support the evolution of the company.
Sequencing errors and subsequent audit could sway product development path and trigger a shift of ongoing studies to a new CRO, possibly impacting the company's financial health and milestones despite strong cash position.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
diamonds : Excuse me, can shares held still be valid after ENDPQ's restructuring?